Newly discovered pathway fuels production of cancer-driving proteins
Researchers identified a previously unknown mechanism that helps cancer cells produce cancer-promoting proteins, including KRAS
Blocking a specific enzyme reduced tumor growth in preclinical models of common cancer types
Loss of the enzyme also improved response to KRAS-targeted drugs and counteracted treatment resistance
The findings suggest this enzyme could be a target for KRAS-driven cancers
A previously unknown mechanism helps...
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
Phase 3 trial finds that next-generation KRAS G12C inhibitor divarasib significantly reduced risk of cancer progressing and death...
ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer
ABSTRACTS: 3438O, 4244RO, 540RO, 2490P
Researchers at The University of Texas MD Anderson Cancer Center presented new findings at the...
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
Patients receiving durvalumab plus olaparib lived almost one year longer than patients treated with chemotherapy alone
Study results were especially encouraging for patients with tumors with mismatch repair proficiency
Updated Phase 3 findings provide the first overall survival analysis demonstrating durable benefits beyond delaying disease progression
ABSTRACT: LBA37
An immunotherapy-based regimen...
Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer in Phase 1b trial
Firmonertinib is an experimental therapy from ArriVent BioPharma for patients with EGFR PACC mutations
PACC mutations make up about...
AI tool reveals what attracts immune cells to tumors and what keeps them away
Researchers developed a new artificial intelligence (AI) tool that can help explain where immune cells gather in the body and what guides them...